HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jennifer R Diamond Selected Research

Biomarkers (Surrogate Marker)

1/2022Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
1/2019Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
12/2018A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
1/2018A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
5/2014Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.
3/2014Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
1/2014Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer.
1/2013Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jennifer R Diamond Research Topics

Disease

42Neoplasms (Cancer)
04/2024 - 12/2009
24Triple Negative Breast Neoplasms
01/2024 - 01/2013
16Breast Neoplasms (Breast Cancer)
06/2023 - 06/2009
9Ovarian Neoplasms (Ovarian Cancer)
02/2024 - 02/2011
6Colorectal Neoplasms (Colorectal Cancer)
02/2024 - 06/2010
3Brain Neoplasms (Brain Tumor)
06/2022 - 07/2014
3Disease Progression
01/2022 - 01/2018
2Adenocarcinoma
04/2024 - 01/2021
2Uterine Cervical Neoplasms (Cancer of the Cervix)
02/2024 - 10/2017
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2024 - 06/2015
2Melanoma (Melanoma, Malignant)
12/2023 - 01/2021
2Carcinoma (Carcinomatosis)
01/2023 - 08/2022
2Neutropenia
01/2022 - 01/2017
2Aneuploidy (Aneuploid)
11/2019 - 10/2018
1Endometrial Neoplasms (Endometrial Cancer)
02/2024
1Heart Failure
11/2023
1Cardiotoxicity
11/2023
1Cardiac Arrhythmias (Arrythmia)
11/2023
1Cardiovascular Diseases (Cardiovascular Disease)
11/2023
1Myocardial Infarction
11/2023
1Interstitial Lung Diseases (Interstitial Lung Disease)
07/2023
1Central Nervous System Diseases (CNS Diseases)
06/2023
1Abdominal Pain (Pain, Abdominal)
01/2022
1Anemia
01/2022
1Hyponatremia
01/2022
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022
1T-Cell Lymphoma (Lymphoma, T Cell)
01/2022
1Limbic Encephalitis (Paraneoplastic Limbic Encephalitis)
02/2021
1Paraneoplastic Cerebellar Degeneration
02/2021
1Encephalitis (Encephalitis, Rasmussen)
02/2021

Drug/Important Bio-Agent (IBA)

10Phosphotransferases (Kinase)IBA
10/2022 - 06/2010
8Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2013
6ENMD 2076IBA
10/2018 - 06/2010
5Irinotecan (Camptosar)FDA LinkGeneric
10/2022 - 12/2018
5Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 06/2015
5Hormones (Hormone)IBA
02/2021 - 03/2020
4MLN 8237IBA
04/2024 - 05/2015
4Aurora Kinase AIBA
04/2024 - 06/2010
4PlatinumIBA
12/2023 - 02/2011
4sacituzumab govitecanIBA
06/2022 - 07/2017
4Immune Checkpoint InhibitorsIBA
01/2021 - 01/2020
4CateninsIBA
11/2020 - 03/2014
3sapanisertibIBA
04/2024 - 01/2020
3Histone Deacetylase InhibitorsIBA
01/2024 - 01/2022
3taxaneIBA
11/2023 - 01/2022
3atezolizumabIBA
01/2021 - 01/2019
2Mechanistic Target of Rapamycin Complex 1IBA
04/2024 - 01/2020
2Histone Deacetylases (Histone Deacetylase)IBA
12/2023 - 01/2022
2AnthracyclinesIBA
11/2023 - 01/2023
2Fulvestrant (Faslodex)FDA Link
05/2023 - 01/2021
2Topoisomerase I InhibitorsIBA
10/2022 - 10/2017
2ErbB Receptors (EGF Receptor)IBA
02/2021 - 07/2014
2adavosertibIBA
01/2021 - 03/2020
2Capecitabine (Xeloda)FDA Link
01/2021 - 03/2020
2RX-5902IBA
11/2020 - 11/2019
2130-nm albumin-bound paclitaxelIBA
01/2020 - 01/2019
2Ado-Trastuzumab EmtansineIBA
01/2019 - 07/2014
2Monoclonal AntibodiesIBA
01/2019 - 06/2015
2Immunoconjugates (Immunoconjugate)IBA
07/2017 - 03/2016
2Aurora KinasesIBA
01/2013 - 02/2011
1monalizumabIBA
02/2024
1LigandsIBA
02/2024
1durvalumabIBA
02/2024
1Granzymes (Granzyme)IBA
02/2024
1ChemokinesIBA
02/2024
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2024
1binimetinibIBA
12/2023
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2023
1DepsipeptidesIBA
12/2023
1omega-Chloroacetophenone (Mace)IBA
11/2023
1trastuzumab deruxtecanIBA
07/2023
1Cyclin D1IBA
06/2023
1Letrozole (Femara)FDA LinkGeneric
06/2023
1palbociclibIBA
06/2023
1tucatinibIBA
06/2023
1Aromatase InhibitorsIBA
06/2023
1AndrogensIBA
05/2023
1enzalutamideIBA
05/2023
1Fluorouracil (Carac)FDA LinkGeneric
10/2022
1AZD0156IBA
10/2022
1Nuclear Proteins (Protein, Nuclear)IBA
08/2022
1Proteins (Proteins, Gene)FDA Link
08/2022
1Alkaline PhosphataseIBA
01/2022
1Histones (Histone)IBA
01/2022
1Protein Isoforms (Isoforms)IBA
01/2022
1Cyclin-Dependent Kinase 9IBA
01/2022
1pertuzumabIBA
06/2021
1Trastuzumab (Herceptin)FDA Link
06/2021
1neratinibIBA
06/2021
1AntibodiesIBA
02/2021
1anti-Yo autoantibodiesIBA
02/2021
1human ERBB2 proteinIBA
02/2021
1pembrolizumabIBA
01/2021
1Opioid Analgesics (Opioids)IBA
01/2021
1Carboplatin (JM8)FDA LinkGeneric
01/2021

Therapy/Procedure

16Therapeutics
04/2024 - 06/2009
10Drug Therapy (Chemotherapy)
11/2023 - 01/2014
3Adjuvant Chemotherapy
11/2023 - 01/2022
2Immunotherapy
01/2021 - 01/2021
1Oral Administration
01/2022